Likewise, a study involving 7858 lung cancer patients which compared mutations between patients aged ≤45 vs >45 years observed a higher prevalence of ALK, ROS1 and RET fusions, ERBB2 exon-20 insertions and EGFR exon-19 deletions in younger patients (16). This evidence concerns the gene ALK and lung carcinoma.